The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers.
about
Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinibSystematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer.Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to dateDrug resistance profiles of mutations in the RET kinase domain
P2860
The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers.
description
2017 nî lūn-bûn
@nan
2017 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
The activity, safety, and evol ...... d non-small cell lung cancers.
@ast
The activity, safety, and evol ...... d non-small cell lung cancers.
@en
The activity, safety, and evol ...... d non-small cell lung cancers.
@nl
type
label
The activity, safety, and evol ...... d non-small cell lung cancers.
@ast
The activity, safety, and evol ...... d non-small cell lung cancers.
@en
The activity, safety, and evol ...... d non-small cell lung cancers.
@nl
prefLabel
The activity, safety, and evol ...... d non-small cell lung cancers.
@ast
The activity, safety, and evol ...... d non-small cell lung cancers.
@en
The activity, safety, and evol ...... d non-small cell lung cancers.
@nl
P2093
P2860
P356
P1476
The activity, safety, and evol ...... d non-small cell lung cancers.
@en
P2093
Alexander Drilon
Alison M Schram
Chebli Mrad
Fernando C Santini
Isabella Bergagnini
Joshua K Sabari
Kathryn C Arbour
Ruqin Chen
W Victoria Lai
P2860
P304
P356
10.2147/OTT.S109295
P407
P577
2017-04-06T00:00:00Z